THOMAS A. HOFFMAN, M.D.; WARD E. BULLOCK, M.D., F.A.C.P.
The activity of carbenicillin against Pseudomonas aeruginosa in vitro and its clinical effectiveness when used as the sole antibiotic treatment of serious infections were evaluated. Seventeen patients with serious pseudomonas infections and three patients with other Gram-negative bacillary infections were treated with carbenicillin. Although most patients showed improvement, only six were cured. The initial pathogenic species was not eradicated from 13 patients, and 5 relapsed due to P. aeruginosa with marked resistance to carbenicillin. The majority of P. aeruginosa isolated from patients after therapy were markedly resistant to carbenicillin (minimum inhibitory concentration, 125 to >500 µg/ml). Superinfections were noted in six patients and were usually caused by Klebsiella-Enterobacter-Serratia or Candida species. Manifestations of hypersensitivity to carbenicillin included drug fever and eosinophilia. Seizures were induced in two azotemic patients on 4 g carbenicillin per day, and pulmonary edema developed in one patient who was receiving 24 g/day.
HOFFMAN TA, BULLOCK WE. Carbenicillin Therapy of Pseudomonas and Other Gram-Negative Bacillary Infections. Ann Intern Med. 1970;73:165–171. doi: 10.7326/0003-4819-73-2-165
Download citation file:
© 2019
Published: Ann Intern Med. 1970;73(2):165-171.
DOI: 10.7326/0003-4819-73-2-165
Infectious Disease.
Results provided by: